Publication: Genome Editing in Engineered T Cells for Cancer Immunotherapy
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Date
Date
Date
Citations
Bonini, C., Chapuis, A. G., Hudecek, M., Guedan, S., Magnani, C., & Qasim, W. (2023). Genome Editing in Engineered T Cells for Cancer Immunotherapy. Human Gene Therapy, 34(17–18), 853–869. https://doi.org/10.1089/hum.2023.128
Abstract
Abstract
Abstract
Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editi
Additional indexing
Creators (Authors)
- Bonini, Chiara
- Chapuis, Aude G
- Hudecek, Michael
- Guedan, Sonia
- Magnani, Chiara
- Qasim, Waseem
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Citations
Bonini, C., Chapuis, A. G., Hudecek, M., Guedan, S., Magnani, C., & Qasim, W. (2023). Genome Editing in Engineered T Cells for Cancer Immunotherapy. Human Gene Therapy, 34(17–18), 853–869. https://doi.org/10.1089/hum.2023.128
